Recursion Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Recursion Pharmaceuticals
RXRX Stock  USD 6.39  0.45  6.58%   
Recursion Pharmaceuticals financial statements provide useful quarterly and yearly information to potential Recursion Pharmaceuticals investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Recursion Pharmaceuticals financial statements helps investors assess Recursion Pharmaceuticals' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Recursion Pharmaceuticals' valuation are summarized below:
Gross Profit
-300.8 M
Market Capitalization
2.7 B
Enterprise Value Revenue
38.7047
Revenue
58.8 M
Earnings Share
(1.69)
We have found one hundred twenty available trending fundamental ratios for Recursion Pharmaceuticals, which can be analyzed and compared to other ratios and to its competitors. All investors should make sure to check out all of Recursion Pharmaceuticals recent market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to rise to about 2.2 B in 2025. Enterprise Value is likely to rise to about 1.8 B in 2025

Recursion Pharmaceuticals Total Revenue

61.78 Million

Check Recursion Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Recursion Pharmaceuticals' main balance sheet or income statement drivers, such as Net Interest Income of 14.9 M, Interest Income of 16.5 M or Depreciation And Amortization of 38.3 M, as well as many indicators such as Price To Sales Ratio of 29.93, Dividend Yield of 0.0 or PTB Ratio of 1.88. Recursion financial statements analysis is a perfect complement when working with Recursion Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Recursion Pharmaceuticals Correlation against competitors.
For more information on how to buy Recursion Stock please use our How to Invest in Recursion Pharmaceuticals guide.

Recursion Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.5 B1.4 B390.5 M
Slightly volatile
Short and Long Term Debt Total113.9 M108.5 M32.1 M
Slightly volatile
Other Current Liabilities86 M81.9 M21.4 M
Slightly volatile
Total Current Liabilities196.8 M187.5 M44.6 M
Slightly volatile
Other Liabilities84.8 M80.8 M22.4 M
Slightly volatile
Property Plant And Equipment Net244.9 M233.2 M65.9 M
Slightly volatile
Accounts Payable22.7 M21.6 M4.3 M
Slightly volatile
Cash394.7 M594.4 M198.5 M
Slightly volatile
Non Current Assets Total771 M734.3 M138 M
Slightly volatile
Non Currrent Assets Other15.2 M14.5 M3.8 M
Slightly volatile
Other Assets1.091.151.5 M
Pretty Stable
Long Term Debt20 M19 M11.1 M
Pretty Stable
Cash And Short Term Investments437.1 M594.4 M215.7 M
Slightly volatile
Net Receivables51.6 M49.2 M7.3 M
Slightly volatile
Common Stock Shares Outstanding212.6 M274.2 M179 M
Slightly volatile
Liabilities And Stockholders Equity1.5 B1.4 B390.5 M
Slightly volatile
Non Current Liabilities Total154.7 M226.3 M205.4 M
Pretty Stable
Capital Lease Obligations85.1 M81 M19.8 M
Slightly volatile
Other Current Assets74.3 M70.8 M14.2 M
Slightly volatile
Total Liabilities296.5 M413.8 M246.6 M
Pretty Stable
Property Plant And Equipment Gross310.7 M295.9 M77.9 M
Slightly volatile
Short and Long Term Debt8.8 M8.4 M1.2 M
Slightly volatile
Total Current Assets477.2 M714.3 M235.5 M
Slightly volatile
Net Working Capital393.3 M526.8 M197.9 M
Slightly volatile
Short Term Debt23.3 M22.2 M4.5 M
Slightly volatile
Property Plant Equipment146.6 M139.7 M54 M
Slightly volatile
Current Deferred Revenue38.5 M61.8 M19.6 M
Slightly volatile
Good Will156.3 M148.9 M23 M
Slightly volatile
Intangible Assets352.6 M335.9 M47.2 M
Slightly volatile
Common Stock Total Equity1.6 K1.8 K2 K
Slightly volatile
Long Term Debt Total506.4 K569.7 K621.1 K
Slightly volatile
Capital Surpluse754.5 M848.8 M925.5 M
Slightly volatile
Deferred Long Term Liabilities3.3 M3.7 M4 M
Slightly volatile
Non Current Liabilities Other8.3 M4.3 M13.4 M
Slightly volatile
Common Stock2.8 K4 K2.2 K
Slightly volatile

Recursion Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income16.5 M15.8 M4.7 M
Slightly volatile
Depreciation And Amortization38.3 M36.5 M10.4 M
Slightly volatile
Interest Expense889.5 K1.6 M829.7 K
Pretty Stable
Selling General Administrative187.1 M178.2 M51.9 M
Slightly volatile
Total Revenue61.8 M58.8 M14.7 M
Slightly volatile
Other Operating Expenses286.5 M537.8 M151.7 M
Slightly volatile
Research Development175.2 M314.4 M96.5 M
Slightly volatile
Cost Of Revenue33.9 M45.2 M43.8 M
Pretty Stable
Total Operating Expenses261.4 M492.6 M141.6 M
Slightly volatile
Reconciled Depreciation38.3 M36.5 M9.7 M
Slightly volatile
Selling And Marketing Expenses8.3 M9.4 M10.2 M
Slightly volatile

Recursion Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation85.8 M81.7 M17.6 M
Slightly volatile
Begin Period Cash Flow295.9 M401.4 M128.2 M
Slightly volatile
Other Cashflows From Financing Activities7.7 M8.1 M25.4 M
Pretty Stable
Depreciation38.3 M36.5 M9.3 M
Slightly volatile
Capital Expenditures20.8 M13.7 M10.6 M
Slightly volatile
Issuance Of Capital Stock267.6 M300.4 M175.4 M
Slightly volatile
Total Cash From Financing Activities261 M304.1 M173 M
Slightly volatile
End Period Cash Flow403.6 M603 M205.1 M
Slightly volatile
Change To Netincome47.4 M45.2 M13.2 M
Slightly volatile
Change To Inventory1.7 K1.8 K3.5 M
Slightly volatile
Sale Purchase Of Stock377.1 M424.2 M462.5 M
Slightly volatile
Change Receivables91.2 K102.6 K111.9 K
Slightly volatile
Cash And Cash Equivalents Changes22.5 M25.4 M27.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio29.9331.50361.2 K
Slightly volatile
Days Sales Outstanding32030584.1552
Slightly volatile
Stock Based Compensation To Revenue0.911.38830.9399
Slightly volatile
Capex To Depreciation0.360.37531.6477
Very volatile
EV To Sales22.0823.24621.1 K
Slightly volatile
Inventory Turnover35.6433.9415.629
Slightly volatile
Days Of Inventory On Hand10.5711.1334.6049
Slightly volatile
Payables Turnover1.992.093128.1777
Slightly volatile
Sales General And Administrative To Revenue5.833.02838.5831
Slightly volatile
Research And Ddevelopement To Revenue5.085.343819.9732
Slightly volatile
Capex To Revenue0.220.23281.9042
Slightly volatile
Cash Per Share1.632.16751.1028
Slightly volatile
Days Payables Outstanding18317440.3577
Slightly volatile
Income Quality0.790.77460.8363
Slightly volatile
Intangibles To Total Assets0.350.33460.0574
Slightly volatile
Net Debt To EBITDA1.831.13861.2557
Slightly volatile
Current Ratio3.623.819.7026
Slightly volatile
Receivables Turnover1.141.196710.4654
Slightly volatile
Capex Per Share0.080.04990.0569
Slightly volatile
Revenue Per Share0.230.21460.0667
Slightly volatile
Interest Debt Per Share0.420.40140.1598
Slightly volatile
Debt To Assets0.08360.07490.1234
Slightly volatile
Operating Cycle320305117
Slightly volatile
Days Of Payables Outstanding18317440.3577
Slightly volatile
Ebt Per Ebit1.090.97030.9964
Pretty Stable
Quick Ratio3.623.819.1916
Slightly volatile
Net Income Per E B T1.090.99761.009
Very volatile
Cash Ratio3.013.17038.6174
Slightly volatile
Days Of Inventory Outstanding10.5711.1334.6049
Slightly volatile
Days Of Sales Outstanding32030584.1552
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.291.03811.119
Slightly volatile
Fixed Asset Turnover0.180.25230.1324
Slightly volatile
Debt Ratio0.08360.07490.1234
Slightly volatile
Price Sales Ratio29.9331.50361.2 K
Slightly volatile
Asset Turnover0.0280.04060.0244
Slightly volatile

Recursion Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.2 B1.9 B2.7 B
Slightly volatile
Enterprise Value1.8 B1.4 B2.3 B
Slightly volatile

Recursion Fundamental Market Drivers

Cash And Short Term Investments594.4 M

Recursion Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Recursion Pharmaceuticals Financial Statements

Recursion Pharmaceuticals investors use historical fundamental indicators, such as Recursion Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Recursion Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue61.8 M38.5 M
Total Revenue58.8 M61.8 M
Cost Of Revenue45.2 M33.9 M
Stock Based Compensation To Revenue 1.39  0.91 
Sales General And Administrative To Revenue 3.03  5.83 
Research And Ddevelopement To Revenue 5.34  5.08 
Capex To Revenue 0.23  0.22 
Revenue Per Share 0.21  0.23 
Ebit Per Revenue(8.14)(8.55)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
VVisa Class A
CRMSalesforce
CRMSalesforce

Additional Tools for Recursion Stock Analysis

When running Recursion Pharmaceuticals' price analysis, check to measure Recursion Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Recursion Pharmaceuticals is operating at the current time. Most of Recursion Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Recursion Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Recursion Pharmaceuticals' price. Additionally, you may evaluate how the addition of Recursion Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY